医疗设备制造商Dilon Technologies完成900万美元融资-动脉网

Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing

CISION 等信源发布 2025-06-09 20:02



可切换为仅中文







NEWPORT NEWS, Va.

纽波特纽斯，弗吉尼亚州

，

June 9, 2025

2025年6月9日

/PRNewswire/ --

/美通社/ --

Dilon Technologies

迪隆科技

, a global leader in medical devices for biosurgery and breast cancer treatment and diagnosis, today announced a

，一家在全球生物手术和乳腺癌治疗及诊断医疗器械领域的领导者，今天宣布了

$9 million

900万美元

growth capital investment from JGB Management Inc. The investment will support Dilon's continued double-digit revenue growth and operational scaling.

来自JGB Management Inc. 的增长资本投资。该投资将支持Dilon持续的两位数收入增长和运营规模扩大。

Dilon Technologies has built a robust presence in surgical settings with a portfolio of products that improve clinical outcomes.

Dilon Technologies凭借其改善临床效果的产品组合，在外科领域建立了强大的影响力。

'We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide,' said

“我们很自豪能与JGB合作，共同推进我们在全球提供基于证据的外科手术解决方案的使命，”

George Makhoul

乔治·马胡勒

, CEO of Dilon Technologies. 'This funding empowers us to continue delivering best-in-class innovations that improve patient care.'

，Dilon Technologies首席执行官。“这笔资金使我们能够继续提供一流的创新技术，从而改善患者护理。”

HEMOBLAST Bellows

血液鼓风机

is a groundbreaking advanced hemostatic agent used in a wide range of surgeries—including cardiac, general, and orthopedic procedures. It remains the only FDA-approved product specifically indicated for the control of minimal, mild, and moderate bleeding. Now utilized in several hundred U.S. hospitals, HEMOBLAST.

是一种突破性的先进止血剂，广泛用于各种手术，包括心脏、普通和骨科手术。它仍然是唯一获得FDA批准的专门用于控制轻微、轻度和中度出血的产品。目前已被美国数百家医院使用，HEMOBLAST。

Bellows continues to redefine standards in surgical hemostasis.

贝尔洛斯继续重新定义外科止血的标准。

Another key product,

另一个关键产品，

MarginProbe

边缘探测器

an in-surgery, real-time breast cancer margin assessment device. It enables surgeons to assess lumpectomy margins intraoperatively, significantly reducing the need for repeat surgeries. Clinical studies show MarginProbe

一种手术中实时乳腺癌边缘评估设备。它使外科医生能够在手术过程中评估肿块切除边缘，显著减少再次手术的需要。临床研究表明MarginProbe

reduces re-excision rates by 25% to 80%. A 2025 study published in

将再次切除率降低了25%到80%。2025年发表在

The American Surgeon Journal

美国外科医生期刊

highlighted a 42% reduction in re-excision for patients with DCIS. A next-generation version of the device has been submitted to the FDA, with approval anticipated by year-end.

突显了对于导管原位癌 (DCIS) 患者，再次切除手术减少了 42%。该设备的下一代版本已提交 FDA，预计将在年底前获得批准。

Dilon's

迪伦的

Navigator

导航器

™ Gamma Probe product line, a market-leading tool for radio-guided lymphatic mapping and tumor localization, continues to perform strongly worldwide. A new, enhanced version is expected to launch by late 2025.

™伽马探头产品线是用于放射引导淋巴结定位和肿瘤定位的市场领先工具，继续在全球范围内表现强劲。预计将在2025年底推出全新升级版本。

'We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide,' said

“我们很高兴与Dilon Technologies合作，帮助他们实现向全球提供手术解决方案的使命，”

Brett Cohen

布雷特·科恩

, CEO of JGB Management Inc.

，JGB管理公司首席执行官

For more information, visit

欲了解更多信息，请访问

www.dilon.com

About Dilon Technologies

关于Dilon科技

Inc.

公司

Dilon Technologies

迪隆科技

Inc. is a commercial-stage medical device company that develops, manufactures, and markets innovative technologies used in hemostasis, cancer detection and assessment, and airway management. Dilon's growing surgical portfolio includes:

Inc.是一家处于商业化阶段的医疗器械公司，致力于开发、制造和销售用于止血、癌症检测与评估以及气道管理的创新技术。Dilon不断扩展的外科产品组合包括：

HEMOBLAST Bellows

血液鼓风炉

: The only FDA-approved powder-form hemostatic agent for minimal, mild, and moderate bleeding.

：唯一经FDA批准的用于轻微、轻度和中度出血的粉状止血剂。

MarginProbe

边缘探测器

: A groundbreaking real-time margin assessment tool for breast cancer surgery.

：一种用于乳腺癌手术的开创性实时边缘评估工具。

Navigator™ System: A leading surgical gamma probe for tumor localization and lymphatic mapping.

Navigator™系统：用于肿瘤定位和淋巴结绘图的领先外科伽马探针。

TrueView 100 Pro: A surgical specimen analyzer for intraoperative use.

TrueView 100 Pro：用于术中的手术标本分析仪。

CoPilot VL+

副驾VL+

: A compact, portable video laryngoscope for airway visualization.

一种用于气道可视化的紧凑型便携式视频喉镜。

About JGB Management Inc.

关于JGB管理公司

JGB Management Inc., founded by

JGB Management Inc.，由

Brett Cohen

布雷特·科恩

in 2005, is an alternative asset management firm focused on investing in niche credit-oriented situations. JGB specializes in privately negotiated investments. The firm is based in Westport CT.

2005年成立，是一家专注于投资小众信贷导向型情况的另类资产管理公司。JGB 专门从事私下协商的投资。该公司总部位于康涅狄格州韦斯特波特。

SOURCE Dilon Technologies

来源：Dilon Technologies

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers